دختر جوان با یک ماه مصرف داروهای سنتی برای افزایش وزن!
Rheumatology Rounds
@yazdrheumatologychannel
نگاه دقیق، پویایی، کیفیت، اصل گرایی و ابتکار شعار ماست
Rheumatology Rounds
16 Oct, 14:14
خانم جوان با فشارخون بالا و ANA مثبت اتفاقی بدون معاینه دهان از قبل درخواست آزمایش
Rheumatology Rounds
15 Oct, 10:15
کنگره بین المللی و میان دوره ای جراحان مغز و اعصاب و ستون فقرات ایران،
۲۵-۲۷ مهرماه دانشگاه علوم پزشکی شهید صدوقی یزد
با افتخار میزبان شما هستیم
https://www.yazd2024nsxcongress.ir/fa/
۲۵-۲۷ مهرماه دانشگاه علوم پزشکی شهید صدوقی یزد
با افتخار میزبان شما هستیم
https://www.yazd2024nsxcongress.ir/fa/
Rheumatology Rounds
15 Oct, 03:48
National Institutes of Health (NIH) (.gov)
https://www.ncbi.nlm.nih.gov › pmc
Current management of avascular necrosis of the metacarpal head
https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389567/&ved=2ahUKEwj4s8n-vI-JAxXuS_EDHZ6hIqMQFnoECBUQAQ&usg=AOvVaw1Rx3EVT_TLUHEIIfJAFuMw
https://www.ncbi.nlm.nih.gov › pmc
Current management of avascular necrosis of the metacarpal head
https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389567/&ved=2ahUKEwj4s8n-vI-JAxXuS_EDHZ6hIqMQFnoECBUQAQ&usg=AOvVaw1Rx3EVT_TLUHEIIfJAFuMw
Rheumatology Rounds
14 Oct, 21:54
https://www.instagram.com/reel/C_qWa8YIsfv/?igsh=MW9yczFyZ2E4YXBmaA==
For fun 😊
For fun 😊
Rheumatology Rounds
14 Oct, 18:34
Janus kinase (JAK) inhibitors are a class of medications used to treat various rheumatic diseases, and the choice of which JAK inhibitor to use can depend on the specific condition being treated, as well as individual patient factors. Here are some common JAK inhibitors and their typical uses:
1. Tofacitinib (Xeljanz):
• Indications: Primarily used for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ulcerative colitis.
• Best for: Patients with moderate to severe RA who have had an inadequate response to other DMARDs.
2. Baricitinib (Olumiant):
• Indications: Approved for moderate to severe RA and atopic dermatitis.
• Best for: RA patients who have not responded well to other treatments or those with concomitant conditions like atopic dermatitis.
3. Upadacitinib (Rinvoq):
• Indications: Used for moderate to severe RA, PsA, and atopic dermatitis.
• Best for: Patients with RA who have had an inadequate response to one or more DMARDs.
4. Filgotinib (Jyseleca):
• Indications: Primarily indicated for moderate to severe RA.
• Best for: Patients with RA who may benefit from a selective JAK1 inhibitor.
5. Abrutinib (not a JAK inhibitor but often confused):
• While it’s a BTK inhibitor, it’s worth noting that it’s used in hematologic malignancies rather than rheumatic diseases.
▎Considerations for Choosing a JAK Inhibitor:
• Efficacy: All JAK inhibitors are generally effective, but individual responses can vary.
• Side Effects: Different JAK inhibitors may have different side effect profiles, which can influence choice.
• Comorbidities: The presence of other health conditions may make one option more suitable than another.
• Patient Preference: Oral medications may be preferred by some patients over injections or infusions.
• Cost and Access: Insurance coverage and cost can also play a significant role in treatment choices.
▎Conclusion:
There isn't a universally "best" JAK inhibitor; the choice depends on the specific rheumatic disease, patient characteristics, and treatment history. It's crucial for healthcare providers to assess each patient's unique situation when prescribing these medications. Always consult with a healthcare professional for personalized medical advice.
1. Tofacitinib (Xeljanz):
• Indications: Primarily used for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ulcerative colitis.
• Best for: Patients with moderate to severe RA who have had an inadequate response to other DMARDs.
2. Baricitinib (Olumiant):
• Indications: Approved for moderate to severe RA and atopic dermatitis.
• Best for: RA patients who have not responded well to other treatments or those with concomitant conditions like atopic dermatitis.
3. Upadacitinib (Rinvoq):
• Indications: Used for moderate to severe RA, PsA, and atopic dermatitis.
• Best for: Patients with RA who have had an inadequate response to one or more DMARDs.
4. Filgotinib (Jyseleca):
• Indications: Primarily indicated for moderate to severe RA.
• Best for: Patients with RA who may benefit from a selective JAK1 inhibitor.
5. Abrutinib (not a JAK inhibitor but often confused):
• While it’s a BTK inhibitor, it’s worth noting that it’s used in hematologic malignancies rather than rheumatic diseases.
▎Considerations for Choosing a JAK Inhibitor:
• Efficacy: All JAK inhibitors are generally effective, but individual responses can vary.
• Side Effects: Different JAK inhibitors may have different side effect profiles, which can influence choice.
• Comorbidities: The presence of other health conditions may make one option more suitable than another.
• Patient Preference: Oral medications may be preferred by some patients over injections or infusions.
• Cost and Access: Insurance coverage and cost can also play a significant role in treatment choices.
▎Conclusion:
There isn't a universally "best" JAK inhibitor; the choice depends on the specific rheumatic disease, patient characteristics, and treatment history. It's crucial for healthcare providers to assess each patient's unique situation when prescribing these medications. Always consult with a healthcare professional for personalized medical advice.
3,168
subscribers
1,579
photos
18
videos
